Depression symptoms and hypothyroidism in a population-based study of middle-aged Brazilian women.

BACKGROUND: Overt hypothyroidism is often recognized as an important cause of depression, but in sub-clinical cases, results are inconsistent and most prior studies have involved small samples. METHODS: We evaluated the association between hypothyroidism and depressive symptoms (PRIME-MD) in a population-based study of 1298 middle-aged women living in a large metropolitan city in Brazil. RESULTS: 45.7% presented depressive symptoms, and 12.3% presented hypothyroidism. Multiple logistic regression analysis adjusting for age, race, smoking and body mass index showed that women with TSH>10 mUI/ml had a threefold chance of presenting depressive symptoms compared to those with normal levels of TSH. Among those with clinical hypothyroidism the adjusted OR was 8.7. CONCLUSION: High levels of TSH were associated to an increased chance of developing depression in the general population. Therefore, depressive symptoms must be considered in patients with thyroid dysfunction and depressed patients should be tested for TSH.

Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.

BACKGROUND: Levosimendan is a new inodilatory agent that enhances cardiac contractility via Ca(2+) sensitization and induces vasodilation through the activation of KATP/BKCa. OBJECTIVE: To study the efficacy and safety of levosimendan in a decompensated heart failure (DHF) Brazilian cohort, and in b-adrenergic agonist resistant patients. METHODS: The Brazilian Evaluation of Levosimendan Infusion Efficacy (BELIEF) study was prospective, multicenter, observational and included 182 high-risk DHF patients, all of which received open-label levosimendan. Primary end point was hospital discharge without additional inotropic therapy (responder). Secondary end points were changes in hemodynamics, clinical parameters, and brain natriuretic peptide (BNP). RESULTS: Mortality rate was 14.8%, and 139 of 182 patients were responders. In non responders it was 62.8%. Systolic blood pressure was a predictor of response. In b-adrenergic agonist resistant group, 55.8% were responders. Overall, 54 patients experienced at least one adverse event; most of them resolved either spontaneously or after levosimendan dose reduction. A significant improvement in quality of life was verified at 2-6 months of follow-up (p<0.0001). CONCLUSION: Our results suggest levosimendan infusion as an alternative therapy in the short term management of DHF patients. HF severity can influence the response to levosimendan treatment. Prospective studies are warranted in a Brazilian cohort including Chagas heart disease.

Levosimendana em pacientes com insuficiência cardíaca descompensada: eficácia em uma coorte brasileira. Resultados do estudo BELIEF / Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study

Fundamento: A levosimendana é um novo agente inodilatador que aumenta a contratilidade cardíaca pela sensibilização ao Ca(2+) e induz vasodilatação por meio da ativação dos canais KATP/BKCa. Objetivo: Estudar a eficácia e segurança da levosimendana em uma coorte brasileira portadora de insuficiência cardíaca descompensada e em pacientes resistentes a agonistas b-adrenérgicos. Métodos: O BELIEF (Brazilian Evaluation of Levosimendan Infusion Efficacy) foi um estudo aberto, prospectivo, multicêntrico e observacional realizado com 182 portadores de ICD de alto risco, todos tratados com levosimendana. O desfecho primário do estudo era alta hospitalar sem terapia inotrópica adicional (pacientes que responderam ao tratamento). Os desfechos secundários eram alterações nos parâmetros clínicos e hemodinâmicos e nos níveis de peptídeo natriurético cerebral (BNP). Resultados: A taxa de mortalidade foi de 14,8 por cento, e 139 dos 182 pacientes responderam ao tratamento. Entre os que não responderam, a taxa de mortalidade foi de 62,8 por cento. A pressão arterial sistólica foi um preditor de resposta ao tratamento. No grupo resistente aos agonistas b-adrenérgicos, 55,8 por cento responderam ao tratamento. Ao todo, 54 pacientes tiveram pelo menos um evento adverso, a maioria dos quais desapareceu espontaneamente ou após redução da dose da levosimendana. Houve uma melhora significativa na qualidade de vida entre 2 e 6 meses do acompanhamento (p < 0,0001). Conclusão: Nossos resultados indicam que a infusão de levosimendana é uma terapia alternativa de curto prazo para tratamento de pacientes com ICD. A gravidade da insuficiência cardíaca pode influenciar a resposta ao tratamento com levosimendana. São necessários estudos prospectivos com uma coorte brasileira que inclua também pacientes com doença de Chagas.

Background: Levosimendan is a new inodilatory agent that enhances cardiac contractility via Ca(2+) sensitization and induces vasodilation through the activation of KATP/BKCa. Objective: To study the efficacy and safety of levosimendan in a decompensated heart failure (DHF) Brazilian cohort, and in b-adrenergic agonist resistant patients. Methods: The Brazilian Evaluation of Levosimendan Infusion Efficacy (BELIEF) study was prospective, multicenter, observational and included 182 high-risk DHF patients, all of which received open-label levosimendan. Primary end point was hospital discharge without additional inotropic therapy (responder). Secondary end points were changes in hemodynamics, clinical parameters, and brain natriuretic peptide (BNP). Results: Mortality rate was 14.8 percent, and 139 of 182 patients were responders. In non responders it was 62.8 percent. Systolic blood pressure was a predictor of response. In b-adrenergic agonist resistant group, 55.8 percent were responders. Overall, 54 patients experienced at least one adverse event; most of them resolved either spontaneously or after levosimendan dose reduction. A significant improvement in quality of life was verified at 2-6 months of follow-up (p<0.0001). Conclusion: Our results suggest levosimendan infusion as an alternative therapy in the short term management of DHF patients. HF severity can influence the response to levosimendan treatment. Prospective studies are warranted in a Brazilian cohort including Chagas heart disease.

TSH levels associated with slimming pill use in a population-based study of brazilian women

OBJECTIVE: To determine the consumption of slimming pills (SP) and its association with TSH levels. RESEARCH METHODS AND PROCEDURES: A survey was carried out in Rio de Janeiro (about 5 million inhabitants), Brazil, from June 2004 to April 2005. Households (1,500) were selected using three-stage probability sampling. Women were asked about use of SP, and blood sample was collected. Women were classified as users of SP any time in life, but not in previous two months (n = 293), current users (n = 150), and never users (n = 853). Weighted multivariate regression analyses compared TSH levels among these groups of users. RESULTS: The frequency of use of SP any time in life was 34 percent and the use in the previous two months was 11 percent. Both frequencies were greater among younger and obese women, and among those of high socioeconomic level (p-value < 0.001). TSH level was statistically lower among current users of SP (1.96 mUI/ml; 95 percentCI = 1.93-1.98) compared to previous users 2.83 mUI/ml (95 percentCI = 2.13-3.02) and never users 2.59 mUI/ml (95 percentCI = 2.20-3.21). These differences were still statistically significant after adjusting for age and body mass index. CONCLUSIONS: Use of SP decreased TSH levels among Brazilian women.

OBJETIVO: Determinar a freqüência de uso de fórmulas para emagrecer e sua associação com níveis de TSH. METODOLOGIA: Pesquisa realizada no Rio de Janeiro (5 milhões de habitantes), Brasil, de junho de 2004 a abril de 2005. A população de estudo foram mulheres com 35 anos ou mais, residentes em domicílios particulares permanentes do município do Rio de Janeiro não grávidas e não lactantes. A amostra de domicílios foi obtida por amostragem probabilística conglomerada em três estágios de seleção. As mulheres tiveram amostras de sangue coletadas e responderam a questões sobre uso de fórmulas, chás ou remédios para emagrecer. Quanto ao uso de fórmulas as mulheres foram classificadas em usuárias alguma vez na vida (n = 293), usuárias nos últimos dois meses (n = 150) e não usuárias (n = 853). Os níveis de TSH desses grupos foram comparados através de análise de regressão multivariada, levando em conta o desenho da amostra. RESULTADOS: O uso de fórmulas alguma vez na vida foi relatado por 34 por cento das mulheres e 11 por cento relataram tê-las consumido nos últimos dois meses. As freqüências foram maiores entre as mulheres mais jovens e obesas e de nível sócio-econômico mais elevado (valor de p < 0,001). Os níveis de TSH foram estatisticamente menores entre as usuárias de fórmulas (1,96 mUI/ml; IC 95 por cento = 1,93-1,98) comparados com usuárias prévias 2,83 mUI/ml (IC 95 por cento = 2,13-3,02) e não usuárias 2,59 mUI/ml (IC 95 por cento = 2,20-3,21). As diferenças entre os grupos mantiveram-se estatisticamente significantes após o ajuste por idade e índice de massa corporal. CONCLUSÃO: O uso de fórmulas para emagrecer diminuiu os níveis de TSH em mulheres brasileiras.

Low prevalence of hypothyroidism among black and Mulatto people in a population-based study of Brazilian women.

Objective African-Americans have been shown to have low prevalence of hypothyroidism. Brazil has a high ethnic admixture allowing further exploration into whether environmental factors can explain the ethnic differences. Design A survey, representative of the population of Rio de Janeiro, a large metropolitan city in Brazil. Factors studied included race, parity, income, schooling, and smoking. Population The survey was carried out in Rio de Janeiro whereby households (1500) were selected using three-stage probability sampling. A total of 1298 (86.5%) women participated in the survey (non-response: 13.5%). Measurements TSH from blood drawn at the households. Anti-thyroperoxidase (anti-TPO) antibodies and free T4 were also measured. Results Overall prevalence of hypothyroidism (TSH > 4 mUI/ml or taking medication) was 12.3%. Prevalence was 6.9% in black people, 8.8% in Mulatto people, and 16.7% among white people. The mean serum TSH of the population was 2.65 (95% confidence interval 2.33-2.97). The TSH distribution of black and Mulatto people was shifted to the left compared to white people. After adjustment for age, income, smoking and presence of anti-TPO, Black and Mulatto people were still protected from hypothyroidism. The adjusted odds ratio for black compared to white people was 0.45 (95% CI 0.30-0.68) and for Mulatto people was 0.34 (95% CI 0.18-0.63). Serum TSH levels were significantly lower in smokers than in non-smokers, but there was no association between number of cigarettes smoked and serum TSH level. Conclusions This is the first time it has been demonstrated that Mulatto people have a prevalence of hypothyroidism which lies between that of white and black people, independent of the prevalence of anti-TPO and smoking.

TSH levels associated with slimming pill use in a population-based study of Brazilian women.

OBJECTIVE: To determine the consumption of slimming pills (SP) and its association with TSH levels. RESEARCH METHODS AND PROCEDURES: A survey was carried out in Rio de Janeiro (about 5 million inhabitants), Brazil, from June 2004 to April 2005. Households (1,500) were selected using three-stage probability sampling. Women were asked about use of SP, and blood sample was collected. Women were classified as users of SP any time in life, but not in previous two months (n = 293), current users (n = 150), and never users (n = 853). Weighted multivariate regression analyses compared TSH levels among these groups of users. RESULTS: The frequency of use of SP any time in life was 34% and the use in the previous two months was 11%. Both frequencies were greater among younger and obese women, and among those of high socioeconomic level (p-value < 0.001). TSH level was statistically lower among current users of SP (1.96 mUI/ml; 95%CI = 1.93-1.98) compared to previous users 2.83 mUI/ml (95%CI = 2.13-3.02) and never users 2.59 mUI/ml (95%CI = 2.20-3.21). These differences were still statistically significant after adjusting for age and body mass index. CONCLUSIONS: Use of SP decreased TSH levels among Brazilian women.

Hereditary corticosteroid-binding globulin deficiency due to a missense mutation (Asp367Asn, CBG Lyon) in a Brazilian kindred.

OBJECTIVE: Abnormal corticosteroid-binding globulin (CBG) is an extremely rare condition and only three mutations have been described in four families. The molecular basis of an abnormal CBG in a Brazilian family was studied and correlations between genotype and serum cortisol, cortisol binding capacity (CBC) and CBG levels were determined. SUBJECTS: All 10 family members, comprising three generations, and nine healthy volunteers were studied. MEASUREMENTS: Genomic DNA was extracted from white blood cells from all family members. The human cbg exons 2-5 were amplified by PCR, submitted to automatic sequencing. Cortisol and CBG levels in serum were measured by radioimmunoassay (RIA). CBC in serum was determined using tritiated cortisol and other cortisol binding parameters were calculated through Scatchard analysis. RESULTS: A missense mutation in exon 5 of cbg (1254G --> A; Asp367Asn), recently described as CBG Lyon, was found in all family members. The proband and one sister were homozygous whereas all other family members, including parents, were heterozygous for this mutation. Cortisol levels in the only two homozygotes were lower than in heterozygotes and both were significantly lower as compared to controls (69 and 182 nmol/l vs. 267 +/- 129 nmol/l vs. 459 +/- 195 nmol/l, respectively, P < 0.05). CBC was decreased in the two homozygotes as compared to heterozygotes and in both groups as compared to controls (< 90 and 114 nmol/l vs. 305.0 +/- 81.4 nmol/l vs. 594.8 +/- 59.5 nmol/l, respectively, P < 0.05). CBG levels were lower in homozygotes as compared to heterozygotes and in both as compared to controls (325 and 375 nmol/l vs. 496.75 +/- 50.75 nmol/l vs. 647.25 +/- 87.50 nmol/l, respectively, P < 0.05). CONCLUSIONS: An abnormal CBG resulting from a missense mutation and known as CBG Lyon was found in this Brazilian kindred. This abnormal CBG has decreased affinity for cortisol and results in low or low normal serum cortisol levels in homozygous and heterozygous subjects. Although relative hypotension and fatigue have recently been associated with CBG deficiency in a family with two CBG mutations (null and Lyon), the two homozygous subjects in this kindred were both normotensive and only the proband presented with fatigue.